健脾化痰祛瘀法对肥胖2型糖尿病模型糖脂代谢及IRS-1/PI3K/Akt2信号通路的影响

doi:10.3969/j.issn.1006-6233.2024.08.05

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1762 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨健脾化痰祛瘀法对肥胖2型糖尿病(Type 2 diabetes mellitus,T2DM)大鼠的糖脂代谢作用及其机制。方法: 通过高脂饮食联合小剂量链佐菌素诱导的T2DM大鼠,分组对照组、模型组、健脾化痰祛瘀方低剂量组、健脾化痰祛瘀方中剂量组、健脾化痰祛瘀方高剂量组。ELISA试剂盒检测血清中促炎细胞因子、生化指标和肝脏中与糖代谢相关的关键酶的活性。qPCR检测胰岛素信号通路关键靶点的mRNA水平。采用Western blot法检测肝脏中磷脂酰肌醇3-激酶(PI3K)、磷酸化PI3K(p-PI3K)、蛋白激酶B(Akt)、磷酸化Akt(p-Akt)和葡萄糖转运蛋白2(Glut2)的表达。结果: 与对照组相比,模型组大鼠血清空腹血糖(FBG)、空腹胰岛素(FINS)、总胆固醇(TC)、甘油三酯(TG)、游离脂肪酸(FFA)、低密度脂蛋白胆固醇(LDL-C)水平显著升高,高密度脂蛋白胆固醇(HDL-C)水平显著降低。而与模型组相比,健脾化痰祛瘀方治疗显著降低了FINS、TG、 TC、LDL-C 和 FFA 水平,降低HDL-C水平。此外,与对照组相比,模型组血清CRP、IFN-γ、TNF-α、 IL-6、IL-1β、NO 水平明显升高。然而,与模型组相比,健脾化痰祛瘀方治疗后,这些促炎细胞因子明显下降。与对照组大鼠相比,模型组大鼠中PEPCK、FBPase、G6Pase和GP的活性增加,但通过健脾化痰祛瘀方治疗后这些酶的活性明显降低。此外,与对照组大鼠相比,模型组大鼠中IRS-1、p-PI3K、p-Akt2的表达增加,但通过健脾化痰祛瘀方治疗后IRS-1、p-PI3K、p-Akt2的表达明显降低。结论: 健脾化痰祛瘀法可能通过激活IRS-1/PI3K/Akt2信号通路改善T2DM大鼠的糖脂代谢。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ： 2型糖尿病, 健脾化痰祛瘀法, 糖脂代谢, IRS-1/PI3K/Akt2信号通路

Abstract：Objective: To explore the effects and mechanisms of the spleen-fortifying, phlegm-resolving, and stasis-removing method on glucose and lipid metabolism in rats with type 2 diabetes mellitus (T2DM).Methods: T2DM was induced in rats using a high-fat diet combined with a low dose of streptozotocin. The rats were divided into control, model, and three treatment groups with low, medium, and high doses of the spleen-fortifying, phlegm-resolving, and stasis-removing formula. Serum inflammatory cytokines, biochemical indicators, and key enzyme activities related to glucose metabolism in the liver were measured using ELISA kits. mRNA levels of key insulin signaling pathway targets were detected by qPCR. Western blotting was used to assess the expression of phosphatidylinositol 3-kinase (PI3K), phosphorylated PI3K (p-PI3K), protein kinase B (Akt), phosphorylated Akt (p-Akt), and glucose transporter 2 (Glut2) in the liver.Results: Compared with the control group, the model group had significantly elevated serum levels of fasting blood glucose (FBG), fasting insulin (FINS), total cholesterol (TC), triglycerides (TG), free fatty acids (FFA), and low-density lipoprotein cholesterol (LDL-C), and significantly reduced high-density lipoprotein cholesterol (HDL-C). The treatment with the spleen-fortifying, phlegm-resolving, and stasis-removing formula significantly reduced FINS, TG, TC, LDL-C, and FFA levels, while increasing HDL-C levels compared with the model group. Additionally, serum levels of CRP, IFN-γ, TNF-α, IL-6, IL-1β, and NO were significantly higher in the model group compared to the control group, but were significantly reduced after treatment. The activities of PEPCK, FBPase, G6Pase, and GP enzymes were elevated in the model group but decreased significantly following treatment. Moreover, the expression of IRS-1, p-PI3K, and p-Akt2 was increased in the model group but significantly reduced with the treatment.Conclusion: The spleen-fortifying, phlegm-resolving, and stasis-removing method may improve glucose and lipid metabolism in T2DM rats by activating the IRS-1/PI3K/Akt2 signaling pathway.

Key words： Type 2 diabetes mellitus Spleen-fortifying phlegm-resolving and stasis-removing method Glucose and lipid metabolism IRS-1/PI3K/Akt2 signaling pathway

基金资助:河北省中医药管理局2022年度中医药类科研计划课题,(编号:2022405)

引用本文:

敦志华, 仇亚茹, 魏秀风, 梅建强, 张明, 成立娟, 武海淼. 健脾化痰祛瘀法对肥胖2型糖尿病模型糖脂代谢及IRS-1/PI3K/Akt2信号通路的影响[J]. 河北医学, 2024, 30(8): 1255-1261.
DUN Zhihua, QIU Yaru, WEI Xiufeng, et al. Stasis-Removing Method on Glucose and Lipid Metabolism and the IRS-1/PI3K/Akt2 Signaling Pathway in an Obese Type 2 Diabetes Mellitus Model. HeBei Med, 2024, 30(8): 1255-1261.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2024.08.05 或 http://www.hbyxzzs.cn/CN/Y2024/V30/I8/1255

[1] Ruze R,Liu T,Zou X,et al.Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments[J].Front Endocrinol (Lausanne),2023,21(14):1161521.
[2] Dao L,Choi S,Freeby M.Type 2 diabetes mellitus and cognitive function: understanding the connections[J].Curr Opin Endocrinol Diabetes Obes,2023,30(1):7-13.
[3] 王向歌,刘爱华,郭莉阁.参苓白术散辅助西医对肥胖2型糖尿病患者血糖控制、体质量指数及胰岛β细胞功能的影响[J].潍坊医学院学报,2023,45(6):438-441.
[4] 刘丹丹,秦合伟,高洋,等.中药通过miRNA调控血管内皮细胞损伤防治动脉粥样硬化的作用机制研究进展[J].中国药房,2023,34(12):1524-1528.
[5] 王俊龙,贾慧雨,冯志海,等.中医药调控AMPK信号通路防治肥胖2型糖尿病的研究进展[J].中国实验方剂学杂志,2023,29(21):264-273.
[6] Wickramasinghe ASD, Attanayake AP,Kalansuriya P.Biochemical characterization of high fat diet fed and low dose streptozotocin induced diabetic Wistar rat model[J].Pharmacol Toxicol Methods,2022(113):107144.
[7] Ajala-Lawal RA, Aliyu NO, Ajiboye TO. Betulinic acid improves insulin sensitivity, hyperglycemia, inflammation and oxidative stress in metabolic syndrome rats via PI3K/Akt pathways[J].Arch Physiol Biochem,2020,126(2):107-115.
[8] Deng N,Guo R,Zheng B,et al.IRS-1/PI3K/Akt pathway and miRNAs are involved in whole grain highland barley (Hordeum vulgare L.) ameliorating hyperglycemia of db/db mice[J].Food Funct,2020,11(11):9535-9546.
[9] 刘军彤.中药益糖康激活FXR受体下调PEPCK与G6Pase表达对T2DM大鼠肝糖异生的作用研究[D].辽宁中医药大学,2020.
[10] Nagy L,Marton J,Vida A, et al.Glycogen phosphorylase inhibition improves beta cell function[J].Br Pharmacol,2018,175(2):301-319.
[11] Thomas M C,Neuen B L,Twigg S M,et al.SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review[J].Endocr Connect,2023,12(8):230005.